TILs & PD-L1 Training Course
We are happy to invite you to participate in our first combined “TILs and PD-L1 Training Course”.
This initiative was initiated considering the increasing importance of TILs and PD-L1 in daily and trial practices, mostly for Triple-Negative Breast Cancer (TNBC). This online educational course provides pathologists training materials on the assessment of TILs. In addition, we provide access to the existing PD-L1 training tools. You will be able to exercise on the same set of digitalized H&E- and PDL1-stained slides of Triple Negative Breast Cancer (TNBC). These slides have been stained with the three most often used PD-L1 assays, namely SP263, SP142 and 22C3. You will be able to evaluate all slides simultaneously.
This training course will be followed later this year by the first External Quality Assessment (EQA) on TILs ever conducted. Both the training and the EQA are organized by the Biomedical Quality Assurance (BQA) Research Unit (University of Leuven, Belgium) in a partnership with the International Immuno-Oncology Biomarker Working Group (also called the TILs Working group).
We invite all interested persons in TILs and PD-L1 assessment to participate in this TILs and PD-L1 Training Course. The course will be open for at least three months. Please transfer this invitation to all those you think may derive benefit from our course.
Participation is free!
CLICK HERE: https://tils.agoko.be/ and consult the instruction manual for a detailed guidance.
Once you have fully completed the training, you will be able to download your certificate of participation.
If you have any further questions, please do not hesitate to contact us.
- THE BIOMEDICAL QUALITY ASSURANCE (BQA) RESEARCH UNIT:
- INTERNATIONAL IMMUNO-ONCOLOGY BIOMARKER WORKING GROUP:
- Email: email@example.com
On behalf of the BQA Research Group and the TILs Working Group,
Biomedical Quality Assurance (BQA) Researched Unit – Scheme Coordinator
Prof. Dr. Els Dequeker (BQA Research Unit, KU Leuven, Leuven, Belgium)
Dorien Ceusters (BQA Research Unit, KU Leuven, Leuven, Belgium)
International Immuno-Oncology Biomarker Working Group (TILs WG) – Expert Team
Roberto Salgado (Department of Pathology, ZAS-Hospitals, Antwerp, Belgium and Division of Research, Peter Mac Callum Cancer Centre, Melbourne, Australia)
John Bartlett (Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh, UK)
David Rimm (Department of Pathology, Yale University School of Medicine, New Haven, CT, USA)
Balazs Acs (Department of Oncology and Pathology, CCK and Department of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden)
Giuseppe Floris (Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and Department of Pathology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.)
Stefan Michiels (Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay and Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France)
Dieter Peeters (CellCarta NV, Antwerp, Belgium and Department of Pathology, AZ Sint-Maarten, Mechelen, Belgium)
Hugo Horlings (Division of Molecular Pathology and Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands)
Kalliopi Siziopikou (Department of Pathology, Section of Breast Pathology, Northwestern University, Chicago, IL)
Carolien van Deurzen (Department of Pathology, Erasmus Medical Center- Cancer Institute, Rotterdam, the Netherlands)
Carsten Denkert (University Marburg and University Hospital Marburg (UKGM), Marburg, Germany)
Dimitrios Zardavas (BMS Oncology Clinical Development)
Mustimbo Roberts (Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA)
Ely Scott (Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA)
Johan Hartman (Department of Oncology and Pathology, CCK and Department of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden)
This work has been supported by the Breast Cancer Research Foundation, and Bristol Myers Squibb.